Acrux Limited (ACR.AX) Stock
Acrux Limited

Company profile
Australia was its largest region in fiscal year 2025, with 74% of revenue.
Figures from company filings; latest fiscal year ended June 30, 2025.
About Acrux Limited
Acrux Limited, together with its subsidiaries, develops and commercializes topically applied pharmaceutical products in Australia, the United States, Europe, and internationally. The company offers Dapsone 7.5% and 5% gels for the treatment of acne vulgaris; Nitroglycerine 0.4% ointments for the treatment of moderate to severe pain associated with chronic anal fissure; Lidocaine and Prilocaine creams USP 2.5% for local analgesia and pre-treatment for infiltration anesthesia; and estradiol transdermal sprays for women for the treatment of moderate to severe hot flushes associated with menopause under the Lenzetto and Evamist brand names. It also provides laboratory and product development services, including in vitro release testing; formulation development; stability and quality check; analytical; generic and pharma development; regulatory; project management and technology transfer; consulting; and co-development services. The company was incorporated in 1998 and is based in West Melbourne, Australia.
Leadership
- John Warmbrunn — MD, CEO & Director
- Joanna Johnson B.E., BEc, ICAA — CFO & Company Secretary
- Jolanta Airey M.D. — Chief Medical Officer
- Felicia Colagrande B.Sc., BSc (Hons), M.B.A. — Product Development & Technical Affairs Director
- Mark Hyman — Project & Technical Development Director
Where does Acrux make most of its revenue?
Australia: 74% of revenue by region in fiscal year 2025, followed by United States of America (26%).
What companies are similar to Acrux?
Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include CSL Limited (CSL.AX), Mayne Pharma Group Limited (MYX.AX), BTC Health Limited (BTC.AX), Argent BioPharma Limited (RGT.AX).
Company Information
Contact & Links
Data as of .
How to cite: DataPorium, “Acrux Limited (ACR.AX)”, data as of Dec 31, 2025, https://dataporium.tech/stocks/ACR.AX